Doxorubicin is able to promote NF-κB translocation, DNA binding and upregulation of NF-κB dependent transcription leading to expression of a NF-κB-dependent transcriptome associated with tumor growth, migration, metastasis and chemoresistance in mutant p53 MDA-MB231, BT-474 and SKBR3 cells, but not in wild-type p53 MCF-7 cancer cells. The gene discussed is TP53; the disease is neoplasm.